Weight changes following antidiabetic mediation use: Real‐world evidence from health system data

OBJECTIVE: Newer antidiabetic medications such as sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and glucagon‐like peptide 1 receptor agonists (GLP1RA) result in weight loss in clinical trials. However, the real‐world effectiveness remains unclear. The magnitude of weight change associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Beini, Grams, Morgan E., Inker, Lesley A., Chang, Alex R., Selvin, Elizabeth, Shin, Jung‐Im
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535667/
https://www.ncbi.nlm.nih.gov/pubmed/36238229
http://dx.doi.org/10.1002/osp4.600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535667/
https://www.ncbi.nlm.nih.gov/pubmed/36238229
http://dx.doi.org/10.1002/osp4.600

Ejemplares similares